Literature DB >> 1396974

Self tolerance to human A and B histo-blood group antigens exists at the B cell level and cannot be broken by potent polyclonal B cell activation in vitro.

R Rieben1, A Tucci, U E Nydegger, R H Zubler.   

Abstract

It is generally considered that tolerance to self antigens is less complete in B than in T lymphocytes. However, B cell tolerance through either functional inactivation (anergy) or clonal deletion has been demonstrated in transgenic mice. In the present study, we investigated whether B cells specific for self A/B histo-blood group antigens can be detected in normal humans. It is a key feature of the ABO system that all normal individuals make natural antibodies against those A or B carbohydrates which are not present in their organism. To detect B cells by the limiting dilution approach we used a specific enzyme-linked immunosorbent assay for the quantitation of anti-A/B antibodies, and a culture system in which polyclonal B cell activation occurs through cell contact with EL4 thymoma cells. As was reported for other B cell studies, we frequently detected "polyreactive" immunoglobulin (Ig)M (but not IgG) with apparent autoreactivity but of uncertain significance regarding physiologic conditions. However, A- or B-specific B cell responses occurred with selective patterns in agreement with classical blood group serology in 14 individuals with A, B, AB or 0 blood group phenotypes: 1/11,600 B cells made anti-allo A/B IgM and 1/26,500 B cells such as IgG, while only 1/104,000 B cells apparently made anti-self A/B IgM and 1/350,000 B cells such as IgG. This shows self tolerance at the B cell level. Since anergy of B cells can frequently be broken by polyclonal B cell activation in vitro, and EL4 cells are potent B cell stimulators, the present results argue for either a highly resistant anergic state or for clonal deletion of self-A/B histo-blood group-specific human B cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396974     DOI: 10.1002/eji.1830221035

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals.

Authors:  A Mulder; M J Kardol; J Kamp; C Uit Het Broek; G M Schreuder; I I Doxiadis; F H Claas
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  B cells and transplantation tolerance.

Authors:  Allan D Kirk; Nicole A Turgeon; Neal N Iwakoshi
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

3.  Partial tolerance of autoreactive B and T cells to erythrocyte-specific self-antigens in mice.

Authors:  Krystalyn E Hudson; Jeanne E Hendrickson; Chantel M Cadwell; Neal N Iwakoshi; James C Zimring
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 4.  The role of B cells in solid organ transplantation.

Authors:  Jean Kwun; Pinar Bulut; Eugenia Kim; Wasim Dar; Byoungchol Oh; Ravi Ruhil; Neal Iwakoshi; Stuart J Knechtle
Journal:  Semin Immunol       Date:  2011-12-01       Impact factor: 11.130

Review 5.  The origin of anti-GM1 antibodies in neuropathies: the "binding site drift" hypothesis.

Authors:  Pablo H H Lopez; Ricardo D Lardone; Fernando J Irazoqui; Mariana Maccioni; Gustavo A Nores
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

6.  Synthetic blood group antigens for anti-A removal device and their interaction with monoclonal anti-A IgM.

Authors:  Jennifer C Solovan; Heung-Il Oh; Azadeh Alikhani; Shalini Gautam; Katherine Vlasova; Elena Y Korchagina; Nicolai V Bovin; William J Federspiel
Journal:  Transpl Immunol       Date:  2006-09-01       Impact factor: 1.708

7.  Effect of blood type on anti-α-Gal immunity and the incidence of infectious diseases.

Authors:  Alejandro Cabezas-Cruz; Lourdes Mateos-Hernández; Pilar Alberdi; Margarita Villar; Gilles Riveau; Emmanuel Hermann; Anne-Marie Schacht; Jamal Khalife; Margarida Correia-Neves; Christian Gortazar; José de la Fuente
Journal:  Exp Mol Med       Date:  2017-03-10       Impact factor: 8.718

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.